Neurofila-ments and glial fibrillary acidic protein (GFAP) have emerged as promising candidates for examining disease pathophysiology in neurological conditions, such as multiple sclerosis (MS), Alzheimer disease, Parkinson’s disease, and others [1,2,3,4,5]. This evidence concerns the gene GFAP and early-onset autosomal dominant Alzheimer disease.